Viewing nowCombinationSamsita Plus Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.

MFDS item code 202108201 · Approved 2021.12.30 · Insurance code 642308580
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to help improve blood sugar control in patients with type 2 diabetes. It is especially suitable for those who have not previously received diabetes medication or for whom blood sugar control has not been sufficient with monotherapy. This medication may also be used when it is difficult to control blood sugar with monotherapy of metformin or sitagliptin, or as an alternative to the combination therapy with these two drugs. It can be used in conjunction with sulfonylureas, thiazolidinediones, and insulin for more effective blood sugar control. Therefore, it serves as a good adjunct for those who find it difficult to control blood sugar with various treatment methods. Overall, it is used as an effective treatment method for improving blood sugar control.
The dose of this medication for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medication should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received pharmacologic treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Receive This Medication). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medication. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).
This medication contains sitagliptin and metformin, which are used for diabetes treatment. Severe allergic reactions may occur while taking this medication, so if you experience symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck, you should immediately discontinue use and consult a physician. Acute pancreatitis, a serious inflammation of the pancreas, can occur rarely; therefore, if you experience abdominal pain, nausea, vomiting, or fever, you should quickly notify medical personnel. The metformin component in this medication can cause a rare but serious condition called lactic acidosis; if you experience sudden fatigue, muscle pain, difficulty breathing, or abdominal pain, you should immediately visit a hospital. Patients with impaired kidney function or conditions that affect the kidneys, such as dehydration, severe infections, heart failure, or acute myocardial infarction, should not take this medication. Additionally, if you are undergoing imaging tests using iodine contrast agents, you must discontinue taking this medication for a certain period before and after the test, and resume only after confirming that kidney function is normal. It is advisable not to use this medication in pregnant or nursing women, or in children and adolescents under 18 years of age, as its safety has not been established in these populations. During the use of this medication, it is important to maintain regular meals and exercise, as well as regularly monitor blood sugar and kidney function to ensure there are no abnormalities. You should be alert for symptoms of hypoglycemia, especially if taking insulin or other hypoglycemic agents, as the risk of hypoglycemia may increase, necessitating observation of symptoms and consultation with a doctor to adjust the medication dosage if necessary. In case of overdose, you should immediately go to the hospital for appropriate treatment; some components may be removed by dialysis. You should avoid excessive alcohol intake while taking this medication, and patients with liver or kidney dysfunction should be particularly cautious. Additionally, if severe joint pain or skin blisters occur, you should immediately inform medical personnel. This medication may interact with various other medications, so be sure to inform your doctor or pharmacist of any other medications you are taking.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container that does not allow air to pass through, at a temperature between 1 degree and 30 degrees Celsius. Storing it this way will help maintain the effectiveness of the medication and prevent degradation.
Light pink oval film-coated tablet
30 tablets/box[(10 tablets/PTP×3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.